What is it used for?
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- momelotinibmomelotinib
- Form and strength
- TABLET · 100 mg; TABLET · 150 mg; TABLET · 200 mgTABLET · 100 mg; TABLET · 150 mg; TABLET · 200 mg
- Manufacturer / applicant
- GLAXOSMITHKLINE LLCGLAXOSMITHKLINE LLC
100 mg round tablet – brown with an underlined “M” debossed on one side and “100” on the other side. 150 mg triangular tablet – brown with an underlined “M” debossed on one side and “150” on the …100 mg round tablet – brown with an underlined “M” debossed on one side and “100” on the other side. 150 mg triangular tablet – brown with an underlined “M” debossed on one side and “150” on the …
Safety and clinical review
- Risk of InfectionsRisk of Infections
- Thrombocytopenia and NeutropeniaThrombocytopenia and Neutropenia
- HepatotoxicityHepatotoxicity
- Severe Cutaneous Adverse Reactions (SCARs)Severe Cutaneous Adverse Reactions (SCARs)
- Major Adverse Cardiovascular Events (MACE)Major Adverse Cardiovascular Events (MACE)
- ThrombosisThrombosis
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is OJJAARA used for?
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of OJJAARA should I ask about?
TABLET · 100 mg; TABLET · 150 mg; TABLET · 200 mgTABLET · 100 mg; TABLET · 150 mg; TABLET · 200 mg
Read the primary sourceWhat determines the price of OJJAARA?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using OJJAARA?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.